Sex steroid hormones as marker of disease activity in Iraqi women infected with RA
DOI:
https://doi.org/10.61841/jdx47c85Keywords:
menopause, Das28, female hormonal factors, Rheumatoid arthritisAbstract
RA is the autoimmune disease, with a higher prevalence among women, which indicates that female hormonal factors play a role in the disease development. Knowing their effect on the development of RA is clinically important and may contribute to specific preventive strategies in populations at high risk .The aim of this study was to analyze correlation of female hormonal factors with the disease activity of RA..
Samples collection of this study was started in October 2018 to January 2019.which included 225 RA women. The patients were divided into two groups depending on menopause status (pre and post menopause)
.Laboratory tests are included: ACCP, RF, CRP, ESR and hormonal levels of progesterone and Estradiol.
The results showed that the percentage of women who had positive results with CCP was 88%,while those with positive RF results was 71% and who with positive CRP was 97%. Most of women diagnosed with rheumatoid arthritis were at the pre-menopausal period 32.5% (73/225) ,while the percentage of the patients women at post-menopause stage were 67.6% (152/225). The results showed that postmenopausal RA women had sever disease activity than premenopausal women and that declared by high levels of both das28 and ESR value (4.63 ± 0.10) and (47.14 ± 0.69) respectively, in comparison to their lower levels (3.66 ± 0.09) and (36.12 ± 0.81) respectively in premenopausal RA women. However, both groups with high levels in comparison to control. A significant negative correlation between BMI and hormones levels in the studied groups, postmenopausal RA women had high BMI (29.71 ± 0.55 kg/m2) than premenopausal women (26.58 ± 0.28 kg/m2) and that characterized by low levels of both progesterone and E2 value (7.24 ± 0.12 ng/ml) and (0.330 ± 0.05 pg/ml) respectively in comparison to their higher levels (42.03 ± 0.59 ng/ml) and (3.49 ± 0.03 pg/ml) respectively in premenopausal RA women. Moreover, both patients groups were had low levels of hormones in comparison to control.
Conclusion: The results showed that there were a highly significant negative (p< 0.01) correlation between hormonal levels and RA disease severity (Das28).
Downloads
References
[1] E. Mollard, S. Pedro, E. Chakravarty, M. Clowse, R. Schumacher, and K. Michaud, “The impact of menopause on functional status in women with rheumatoid arthritis,” Rheumatology (Oxford)., vol. 57, no. 5, pp. 798–802, 2018, doi: 10.1093/rheumatology/kex526.
[2] C. O. Pozo, The association between hormonal/reproductive factors and the risk of developing rheumatoid arthritis. 2015.
[3] T. Ohshima, H. Inoue, K. Uchihashi, S. Hirano, and Y. Nishikawa, “Effect of IL--12 family cytokines on NK92 cells,” J. Osaka Dent. Univ., vol. 51, no. 2, pp. 115–123, 2017, doi: 10.18905/jodu.51.2_115.
[4] G. C. Hughes and D. Choubey, “Modulation of autoimmune rheumatic diseases by oestrogen and progesterone,” Nat. Rev. Rheumatol., vol. 10, no. 12, pp. 740–751, 2014, doi: 10.1038/nrrheum.2014.144.
[5] M. K. Desai and R. D. Brinton, “Autoimmune Disease in Women: Endocrine Transition and Risk Across the Lifespan,” Front. Endocrinol. (Lausanne)., vol. 10, p. 265, Apr. 2019, doi: 10.3389/fendo.2019.00265.
[6] S. Lecomte, F. Demay, F. Ferrière, and F. Pakdel, “Phytochemicals Targeting Estrogen Receptors: Beneficial Rather Than Adverse Effects?,” Int. J. Mol. Sci., vol. 18, no. 7, p. 1381, Jun. 2017, doi: 10.3390/ijms18071381.
[7] K. Lélu et al., “Estrogen receptor α signaling in T lymphocytes is required for estradiol-mediated inhibition of Th1 and Th17 cell differentiation and protection against experimental autoimmune encephalomyelitis,” J. Immunol., vol. 187, no. 5, pp. 2386–2393, 2011.
[8] V. R. Moulton, “Sex hormones in acquired immunity and autoimmune disease,” Front. Immunol., vol. 9, p. 2279, 2018.
[9] N. M. Shah, P. F. Lai, N. Imami, and M. R. Johnson, “Progesterone-Related Immune Modulation of Pregnancy and Labor,” Front. Endocrinol. (Lausanne)., vol. 10, p. 198, Mar. 2019, doi:
10.3389/fendo.2019.00198.
[10] H. Gong et al., “The regulation of ovary and conceptus on the uterine natural killer cells during early pregnancy,” Reprod. Biol. Endocrinol., vol. 15, no. 1, pp. 1–10, 2017, doi: 10.1186/s12958-017-0290-
1.
[11] Y. Shoenfeld, P. L. Meroni, and M. E. Gershwin, Autoantibodies. Newnes, 2013.
[12] S. Alivernini et al., “Is ACPA positivity the main driver for rheumatoid arthritis treatment? Pros and cons,” Autoimmun. Rev., vol. 16, no. 11, pp. 1096–1102, 2017.
[13] M. Di Cicco, “Improving Prediction Strategies in Rheumatoid Arthritis: Additional Predictive Ability of Synovial Pathotype over Clinical, Laboratory and Imaging Findings.” Queen Mary University of London, 2018.
[14] J. L. Poole, “Hand Function in Rheumatoid Arthritis,” in Hand Function, Springer, 2019, pp. 73–82.
[15] L. A. Merlino, J. R. Cerhan, L. A. Criswell, T. R. Mikuls, and K. G. Saag, “Estrogen and other female reproductive risk factors are not strongly associated with the development of rheumatoid arthritis in elderly women,” in Seminars in arthritis and rheumatism, 2003, vol. 33, no. 2, pp. 72–82.
[16] A. H. Al-Hafidh, G. T. Saeed, and F. L. Goral, “Comparison of lean body mass& body fat mass in pre and postmenopausal women in Baghdad teaching hospital with their impact on bone mineral density,”
J. Pharm. Sci. Res., vol. 10, no. 12, p. 3124, 2018.
[17] A.-B. G. Blavnsfeldt, A. de Thurah, M. D. Thomsen, S. Tarp, B. Langdahl, and E.-M. Hauge, “The effect of glucocorticoids on bone mineral density in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomized, controlled trials,” Bone, vol. 114, pp. 172–180, 2018.
[18] M. L. Krause and A. Makol, “Management of rheumatoid arthritis during pregnancy: challenges and solutions,” Open access Rheumatol. Res. Rev., vol. 8, p. 23, 2016.
[19] C. Roomruangwong, A. F. Carvalho, F. Comhaire, and M. Maes, “Lowered plasma steady-state levels of progesterone combined with declining progesterone levels during the luteal phase predict peri-menstrual syndrome and its major subdomains,” Front. Psychol., vol. 10, p. 2446, 2019.
[20] O. J. Hall et al., “Progesterone-based contraceptives reduce adaptive immune responses and protection against sequential influenza A virus infections,” J. Virol., vol. 91, no. 8, pp. e02160-16, 2017.
[21] A. Silman, A. Kay, and P. Brennan, “Timing of pregnancy in relation to the onset of rheumatoid arthritis,” Arthritis Rheum. Off. J. Am. Coll. Rheumatol., vol. 35, no. 2, pp. 152–155, 1992.
[22] K. S. Korach et al., “Physiological and Pathological Roles of Estrogen Receptor,” in Estrogen Receptor and Breast Cancer, Springer, 2019, pp. 15–47.
[23] I. Mohammad et al., “Estrogen receptor α contributes to T cell–mediated autoimmune inflammation by promoting T cell activation and proliferation,” Sci. Signal., vol. 11, no. 526, p. eaap9415, 2018.
[24] K. Shimizu et al., “Mucosal immune function comparison between amenorrheic and eumenorrheic distance runners,” J. Strength Cond. Res., vol. 26, no. 5, pp. 1402–1406, 2012.
[25] M. Mori, F. Tsukahara, T. Yoshioka, K. Irie, and H. Ohta, “Suppression by 17β-estradiol of monocyte adhesion to vascular endothelial cells is mediated by estrogen receptors,” Life Sci., vol. 75, no. 5, pp. 599–609, 2004.
[26] B. Fazekas de St Groth, E. Zhu, S. Asad, and L. Lee, “Flow cytometric detection of human regulatory T cells.,” Methods in molecular biology (Clifton, N.J.), vol. 707. pp. 263–279, 2011, doi: 10.1007/978-1-61737-979-6_17.
[27] H. S. Jeong, S. J. Hong, S. J. Choi, J.-H. Kim, G. G. Song, and J. H. Jung, “Effects of oral contraceptives on rheumatoid arthritis in Korean menopausal women: a nationwide cross-sectional study,” Maturitas, vol. 112, pp. 24–28, 2018.
[28] Y. A. De Man, R. J. E. M. Dolhain, F. E. Van De Geijn, S. P. Willemsen, and J. M. W. Hazes, “Disease activity of rheumatoid arthritis during pregnancy: results from a nationwide prospective study,” Arthritis Care Res. Off. J. Am. Coll. Rheumatol., vol. 59, no. 9, pp. 1241–1248, 2008.
[29] M. Østensen and M. Wallenius, “Fertility and pregnancy in rheumatoid arthritis,” Indian J. Rheumatol., vol. 11, no. 6, p. 122, 2016.
[30] C. M. Gameiro, F. Romão, and C. Castelo-Branco, “Menopause and aging: changes in the immune system—a review,” Maturitas, vol. 67, no. 4, pp. 316–320, 2010.
[31] A. Lateef and M. Petri, “Hormone replacement and contraceptive therapy in autoimmune diseases,” J. Autoimmun., vol. 38, no. 2–3, pp. J170–J176, 2012.
[32] A. Andersson, “Estrogens and interleukin-17 in arthritis and associated osteoporosis,” 2016.
[33] C. Salliot, C. Bombardier, A. Saraux, B. Combe, and M. Dougados, “Hormonal replacement therapy may reduce the risk for RA in women with early arthritis who carry HLA-DRB1* 01 and/or* 04 alleles by protecting against the production of anti-CCP: results from the ESPOIR cohort,” Ann. Rheum. Dis., vol. 69, no. 9, pp. 1683–1686, 2010.
[34] J. A. Roman-Blas, S. Castañeda, M. Cutolo, and G. Herrero-Beaumont, “Efficacy and safety of a selective estrogen receptor β agonist, ERB-041, in patients with rheumatoid arthritis: A 12-week, randomized, placebo-controlled, phase II study,” Arthritis Care Res. (Hoboken)., vol. 62, no. 11, pp. 1588–1593, 2010.
[35] C. Orellana, S. Saevarsdottir, L. Klareskog, E. W. Karlson, L. Alfredsson, and C. Bengtsson, “Oral contraceptives, breastfeeding and the risk of developing rheumatoid arthritis: results from the Swedish EIRA study,” Ann. Rheum. Dis., vol. 76, no. 11, pp. 1845–1852, 2017.
[36] E. W. Karlson, L. A. Mandl, S. E. Hankinson, and F. Grodstein, “Do breast-feeding and other reproductive factors influence future risk of rheumatoid arthritis?: Results from the Nurses’ Health
Study,” Arthritis Rheum., vol. 50, no. 11, pp. 3458–3467, 2004.
[37] K. Albrecht, J. Callhoff, F. Buttgereit, R. H. Straub, G. Westhoff, and A. Zink, “Association Between the Use of Oral Contraceptives and Patient-Reported Outcomes in an Early Arthritis Cohort,” Arthritis Care Res. (Hoboken)., vol. 68, no. 3, pp. 400–405, 2016.
[38] G. C. Hughes, “Progesterone and autoimmune disease,” Autoimmun. Rev., vol. 11, no. 6–7, pp. A502–A514, 2012.
[39] A. Andersson, Estrogens and interleukin-17 in arthritis and associated osteoporosis. 2016.
[40] H. Offner, K. Adlard, A. Zamora, and A. A. Vandenbark, “Estrogen potentiates treatment with T-cell receptor protein of female mice with experimental encephalomyelitis,” J. Clin. Invest., vol. 105, no. 10, pp. 1465–1472, 2000.
[41] V. Taneja, “Sex hormones determine immune response,” Front. Immunol., vol. 9, p. 1931, 2018.
[42] J.-F. Arnal et al., “Estrogen receptors and endothelium,” Arterioscler. Thromb. Vasc. Biol., vol. 30, no. 8, pp. 1506–1512, 2010.
[43] C. Schairer et al., “Quantifying the Role of Circulating Unconjugated Estradiol in Mediating the Body Mass Index-Breast Cancer Association,” Cancer Epidemiol. Biomarkers Prev., vol. 25, no. 1, pp. 105–113, Jan. 2016, doi: 10.1158/1055-9965.EPI-15-0687.
[44] G. Nikolic et al., “Pain, Physical Function, Radiographic Features, and Quality of Life in Knee Osteoarthritis Agricultural Workers Living in Rural Population,” Pain Res. Manag., vol. 2019, 2019.
[45] X. Feng et al., “Body mass index and the risk of rheumatoid arthritis: an updated dose-response meta-analysis,” Biomed Res. Int., vol. 2019, 2019.
[46] B. Qin et al., “Body mass index and the risk of rheumatoid arthritis: a systematic review and dose-response meta-analysis,” Arthritis Res. Ther., vol. 17, no. 1, p. 86, 2015.
[47] J. Feng et al., “Body mass index and risk of rheumatoid arthritis: a meta-analysis of observational studies,” Medicine (Baltimore)., vol. 95, no. 8, 2016.
[48] C. L. Santos, L. D. Bobermin, D. O. Souza, and A. Quincozes-Santos, “Leptin stimulates the release of pro-inflammatory cytokines in hypothalamic astrocyte cultures from adult and aged rats,” Metab. Brain Dis., vol. 33, no. 6, pp. 2059–2063, 2018.
[49] X. Jin et al., “Associations between endogenous sex hormones and MRI structural changes in patients with symptomatic knee osteoarthritis,” Osteoarthr. Cartil., vol. 25, no. 7, pp. 1100–1106, 2017.
[50] O. Bereshchenko, S. Bruscoli, and C. Riccardi, “Glucocorticoids, sex hormones, and immunity,”
Front. Immunol., vol. 9, p. 1332, 2018.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
